Inside Look: AdvaMed Pursuing a Six-Point Plan for Success

For the final Inside Look of 2011, we're turning the spotlight on two of industry's biggest advocacy groups: AdvaMed and MDMA. Read on to get the scoop on AdvaMed, or learn more about how MDMA's year went.

November 29, 2011

2 Min Read
Inside Look: AdvaMed Pursuing a Six-Point Plan for Success

For the final Inside Look of 2011, we're turning the spotlight on two of industry's biggest advocacy groups: AdvaMed and MDMA. Read on to get the scoop on AdvaMed, or learn more about how MDMA's year went

October: Korea Free Trade Agreement signed. AdvaMed applauds the measure when it is passed in October.September: AdvaMed 2011, the group’s annual conference, features former President George W. Bush.July: IOM 510(k) report falters. Ubl says the group was initially concerned about the notorious report, but he’s glad to say that it has “fallen flat” since.Yearlong: Legislators continue to combat the medical device excise tax. Several bills to repeal the tax have been introduced during this session of Congress, including one that’s gaining steam.

Stephen Ubl, president and CEOJim Mazzo, board chairman; president, Abbott Medical OpticsDavid Nexon, senior executive vice president

Between defending the 510(k) program, fighting implementation of the device tax, and pushing for a more accountable and communicative FDA, it’s fair to say AdvaMed had a full plate in 2011.

In addition to all of the hurdles facing device makers specifically, the entire domestic healthcare system is in flux, with the ramifications of the Affordable Care Act still to be determined, not to mention the tumultuous state of the U.S. and global economies. Considering that, says AdvaMed president and CEO Stephen Ubl, “you could argue that it’s perhaps the most challenging environment the industry has faced in a long time.”

Which is where, Ubl says, AdvaMed’s so-called “competitiveness agenda” comes in. The agenda is a six-point plan, released in September, for helping the U.S. device industry hold on to its place atop the global pecking order. The plan calls for the government to focus on innovation in life sciences, reduce FDA review times, improve Medicare and Medicaid reimbursement policies, ensure trade environments are favorable, enact fair tax policies, and boost the domestic R&D efforts.

“Just broadly speaking,” Ubl says, “the competitiveness agenda framework has also allowed us to raise the visibility of [industry’s] concerns and be proactive about the policy areas that need to be addressed to ensure our continued leadership.” 

Ubl indicated that AdvaMed will continue to center its efforts around the agenda as it supports an industry dealing with increasingly complex and difficult realities.

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like